Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Poster Presentation at ASCO GI
January 21, 2020 22:20 ET | Cancer Advances Inc
DURHAM, N.C., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will present a poster at the...
Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson
January 21, 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
Houston manufacturing facility and portions of Bellicum’s Technical Operations and Quality staff to be acquired by MD Anderson Current and future GoCAR™ product candidates to be manufactured by MD...
Bellicum Logo.jpg
Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium
January 16, 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
PMCB YT .png
PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%
January 14, 2020 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double...
Rafael_Pharma-Logo+Slogan.png
Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer
January 14, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
Cranbury, NJ, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
PMCB YT .png
PharmaCyte Biotech Set to Reach Three Major Milestones in 2020
January 06, 2020 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 06, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech’s (OTCQB: PMCB) shareholders should expect 2020 to be the year that ushers in a host of much-anticipated milestones.  This year the...
PMCB YT .png
PharmaCyte Biotech Finalizes Pancreatic Cancer Treatment for U.S. FDA Approval to Begin Clinical Trial
December 11, 2019 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Dec. 11, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has a clinical trial product, a clinical trial protocol, including a clinical trial design, a Principal Investigator,...
PMCB YT .png
PharmaCyte Biotech’s “Release Testing” Last Critical Event Before Submission of Investigational New Drug Application
November 12, 2019 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Nov. 12, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reduced a long list of FDA-required items to just one last important component—release testing—before it can...
Cancer Advances, Inc. announces a new publication “Vaccine Against Gastrin, a Polyclonal Antibody Stimulator, Decreases Pancreatic Cancer Metastases” in the American Journal of Physiology—Gastrointestinal and Liver Physiology
November 11, 2019 03:00 ET | Cancer Advances Inc
Immune competent female mice with pancreatic cancer treated with Polyclonal Antibody Stimulator (PAS) vaccine had significantly smaller tumors and fewer metastases than control mice. PAS vaccine...
Cancer Advances, Inc. announces new publication: “Gastrin Vaccine Improves Response to Immune Checkpoint Antibody in Murine Pancreatic Cancer by Altering the Tumor Microenvironment”, in the journal Cancer Immunology, Immunotherapy
November 11, 2019 02:00 ET | Cancer Advances Inc
Inactivation of the growth peptide gastrin modulates the tumor microenvironment of pancreatic cancer rendering it more susceptible to immune checkpoint antibody therapy.Polyclonal Antibody Stimulator...